Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Blueprint Medicines Corp (NASDAQ: BPMC) closed at $90.48 in the last session, up 0.99% from day before closing price of $89.59. In other words, the price has increased by $0.99 from its previous closing price. On the day, 1.94 million shares were traded. BPMC stock price reached its highest trading level at $91.055 during the session, while it also had its lowest trading level at $88.53.
Ratios:
We take a closer look at BPMC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.85. In the meantime, Its Debt-to-Equity ratio is 2.43 whereas as Long-Term Debt/Eq ratio is at 2.03.
On March 17, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $135.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $150.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $150 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 05 ’25 when Albers Jeffrey W. sold 5,766 shares for $88.80 per share. The transaction valued at 512,021 led to the insider holds 146,630 shares of the business.
Albers Jeffrey W. sold 7,500 shares of BPMC for $658,500 on Mar 12 ’25. The Director now owns 152,396 shares after completing the transaction at $87.80 per share. On Mar 06 ’25, another insider, Hewes L. Becker, who serves as the CHIEF MEDICAL OFFICER of the company, sold 5,232 shares for $87.69 each. As a result, the insider received 458,804 and left with 30,419 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 5782215168 and an Enterprise Value of 5891009024. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.36 while its Price-to-Book (P/B) ratio in mrq is 19.30. Its current Enterprise Value per Revenue stands at 11.578 whereas that against EBITDA is -30.094.
Stock Price History:
The Beta on a monthly basis for BPMC is 0.74, which has changed by 0.0047751665 over the last 52 weeks, in comparison to a change of 0.08275449 over the same period for the S&P500. Over the past 52 weeks, BPMC has reached a high of $121.90, while it has fallen to a 52-week low of $80.68. The 50-Day Moving Average of the stock is -8.69%, while the 200-Day Moving Average is calculated to be -6.99%.
Shares Statistics:
According to the various share statistics, BPMC traded on average about 947.59K shares per day over the past 3-months and 958260 shares per day over the past 10 days. A total of 63.71M shares are outstanding, with a floating share count of 62.64M. Insiders hold about 1.98% of the company’s shares, while institutions hold 106.05% stake in the company. Shares short for BPMC as of 1740700800 were 4708205 with a Short Ratio of 4.97, compared to 1738281600 on 4212968. Therefore, it implies a Short% of Shares Outstanding of 4708205 and a Short% of Float of 8.290000000000001.
